This review highlights that while bradykinin may contribute to the beneficial effects of ACE inhibitors on cardiovascular hypertrophy, AT1 receptor antagonists are also effective, suggesting multiple mechanisms of protection.
No takes yet. Share an insight, caveat, or question.
May support either ACEIs or ARBs for hypertrophy prevention; leaves bradykinin's role unresolved for targeted trials.
Waeber et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: